MNMD Stock Forecast 2025-2026
Distance to MNMD Price Targets
MNMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Mind Medicine (MNMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MNMD and similar high-potential opportunities.
Latest MNMD Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, MNMD has a bullish consensus with a median price target of $20.00 (ranging from $16.00 to $55.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $6.58, the median forecast implies a 204.0% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 735.9% upside. Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 143.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MNMD Analyst Ratings
MNMD Price Target Range
Latest MNMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MNMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | Baird | Joel Beatty | Outperform | Maintains | $16.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $55.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $55.00 |
| Jan 28, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Initiates | $23.00 |
| Dec 20, 2024 | Chardan Capital | Rudy Li | Buy | Initiates | $20.00 |
| Dec 17, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $20.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $55.00 |
| Sep 16, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $14.00 |
| Aug 29, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $55.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $35.00 |
| Jul 24, 2024 | Roth MKM | Jason Wittes | Buy | Maintains | $36.00 |
| Jun 21, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Jun 5, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $22.00 |
| May 28, 2024 | Baird | Joel Beatty | Outperform | Initiates | $27.00 |
| May 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $35.00 |
| May 13, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $20.00 |
| May 10, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $35.00 |
| Apr 15, 2024 | Leerink Partners | Rudy Li | Outperform | Initiates | $20.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Mar 8, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $22.00 |
Mind Medicine (MindMed) Inc. (MNMD) Competitors
The following stocks are similar to Mind Medicine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mind Medicine (MindMed) Inc. (MNMD) Financial Data
Mind Medicine (MindMed) Inc. has a market capitalization of $511.00M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Mind Medicine (MindMed) Inc. (MNMD) Business Model
About Mind Medicine (MindMed) Inc.
Develops psychedelic-inspired medicines for mental health.
Mind Medicine generates revenue through the development and commercialization of novel psychedelic-based therapies aimed at treating mental health disorders. The company engages in clinical trials to validate the efficacy and safety of its products, with the potential for significant returns once these therapies are approved and brought to market.
MindMed is a pioneer in integrating psychedelic research into traditional medical practices, focusing on conditions like anxiety, ADHD, depression, and addiction. The company is part of a larger movement to destigmatize psychedelics and is strategically positioned to capitalize on the growing acceptance of alternative mental health treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Mr. Robert Barrow
Country
United States
IPO Year
2021
Website
www.mindmed.coMind Medicine (MindMed) Inc. (MNMD) Latest News & Analysis
Mind Medicine Inc. (NASDAQ: MNMD) issued inducement grants of options to purchase 88,950 common shares to four new non-executive employees, effective March 24, 2025.
The issuance of stock options to new employees can signal confidence in the company's future and align employee interests with shareholder value, potentially affecting stock performance.
Mind Medicine (MindMed) Inc. has appointed Matt Wiley as Chief Commercial Officer to lead its commercial strategy ahead of the potential launch of its first product, MM12.
Matt Wiley's appointment as CCO signals a focus on commercialization for MindMed, crucial for driving revenue and market positioning ahead of the potential launch of MM12.
Mind Medicine Inc. (NASDAQ: MNMD) will hold its Q4 2024 earnings call on March 6, 2025, at 8:00 AM ET, featuring key executives and analysts from various firms.
The earnings call provides insights into MindMed's financial performance and strategic direction, crucial for assessing its growth potential and investment viability.
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
21 days agoMind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its Q4 and full-year 2024 financial results, highlighting significant progress and milestones in developing treatments for brain health disorders.
MindMed's financial results and milestone achievements signal progress in clinical development, potentially enhancing investor confidence and affecting stock valuation.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will present at Leerink's Global Healthcare Conference on March 11, 2025, at 3:40 PM ET in Miami Beach, FL.
Management presentations at major conferences can boost visibility and investor confidence, potentially impacting stock performance and attracting new investments in MindMed.
Mind Medicine (MindMed) Inc. will host a webcast on March 6, 2025, at 8:00 a.m. ET to report Q4 and full-year 2024 financial results and discuss business updates.
MindMed's upcoming webcast will reveal key financial results and business updates, affecting investor sentiment and stock performance based on growth potential and market response.
Frequently Asked Questions About MNMD Stock
What is Mind Medicine (MindMed) Inc.'s (MNMD) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Mind Medicine (MindMed) Inc. (MNMD) has a median price target of $20.00. The highest price target is $55.00 and the lowest is $16.00.
Is MNMD stock a good investment in 2025?
According to current analyst ratings, MNMD has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MNMD stock?
Wall Street analysts predict MNMD stock could reach $20.00 in the next 12 months. This represents a 204.0% increase from the current price of $6.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mind Medicine (MindMed) Inc.'s business model?
Mind Medicine generates revenue through the development and commercialization of novel psychedelic-based therapies aimed at treating mental health disorders. The company engages in clinical trials to validate the efficacy and safety of its products, with the potential for significant returns once these therapies are approved and brought to market.
What is the highest forecasted price for MNMD Mind Medicine (MindMed) Inc.?
The highest price target for MNMD is $55.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 735.9% increase from the current price of $6.58.
What is the lowest forecasted price for MNMD Mind Medicine (MindMed) Inc.?
The lowest price target for MNMD is $16.00 from Joel Beatty at Baird, which represents a 143.2% increase from the current price of $6.58.
What is the overall MNMD consensus from analysts for Mind Medicine (MindMed) Inc.?
The overall analyst consensus for MNMD is bullish. Out of 12 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are MNMD stock price projections?
Stock price projections, including those for Mind Medicine (MindMed) Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
